Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies Median Progression-Free Survival (PFS): 6.8 months — nearly double the 3.7 months seen with current standard of care (SOC) docetaxel Confirmed Objective Response Rate (ORR): 18.2% — higher than the 12.8% seen with SOC docetaxel Disease Control Rate (DCR: PR + SD > 4 months): 77.3% — indicating clinical benefit majority of patients who progressed on prior PD-1/L1 i ...